Therapeutic Advances in Respiratory Disease This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Experience with indwelling pleural catheters in the treatment of recurrent pleural effusions
Recurrent pleural effusions are frequently encountered in clinical practice. Whether malignant or nonmalignant, they often pose a challenge to the practicing clinician. When they recur, despite optimum medical therapy of the underlying condition and repeated thoracenteses, more invasive definitive approaches are usually required. Since its introduction in 1997, the PleurX catheter became the preferred method to treat recurrent malignant pleural effusions. Since then, a number of publications have documented its utility in managing recurrent nonmalignant pleural effusions. The purpose of this paper is to review the use of t...
Source: Therapeutic Advances in Respiratory Disease - November 27, 2016 Category: Respiratory Medicine Authors: Chalhoub, M., Ali, Z., Sasso, L., Castellano, M. Tags: Reviews Source Type: research

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
This article reviews clinical trial development of osimertinib in patients with NSCLC, presenting efficacy and safety evidence for its value in the EGFR T790M mutation-positive population and in different settings, including patients with metastatic disease. The preclinical background of clinically acquired resistance to osimertinib is presented and the combination tactics being investigated in an attempt to circumvent this are addressed. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - November 27, 2016 Category: Respiratory Medicine Authors: Sullivan, I., Planchard, D. Tags: Reviews Source Type: research

The clinical profile of benralizumab in the management of severe eosinophilic asthma
Despite several therapeutic choices, 10–20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and interventional, that can result in improvement of severe asthma management, such as omalizumab, bronchial thermoplasty and other biological drugs, for example, mepolizumab, reslizumab and benralizumab. The availability of these new treatments and the increasing knowledge of the different asthmatic phenotypes and endotypes ma...
Source: Therapeutic Advances in Respiratory Disease - November 27, 2016 Category: Respiratory Medicine Authors: Menzella, F., Lusuardi, M., Galeone, C., Facciolongo, N., Zucchi, L. Tags: Reviews Source Type: research

Tiotropium in the add-on treatment of asthma in adults: clinical trial evidence and experience
Asthma is a chronic inflammatory airway disease, and its treatment is frequently challenging despite detailed national and international guidelines. While basic anti-inflammatory therapy usually consists of inhaled corticosteroids in doses adapted to the asthma severity, add-on treatment with bronchodilators is essential in more severe asthma. Only recently, the long-acting anticholinergic tiotropium was introduced into the GINA guidelines. This review reports on the studies that have been performed with tiotropium in adult asthmatic patients. Following early proof-of-concept studies, several studies with tiotropium as an ...
Source: Therapeutic Advances in Respiratory Disease - November 27, 2016 Category: Respiratory Medicine Authors: Vogelberg, C. Tags: Reviews Source Type: research

A simple method of bronchial occlusion with silicone spigots (Endobronchial Watanabe Spigot; EWS(R)) using a curette
Conclusions: EWS bronchial occlusion using a curette is a simple method for managing intractable bronchopleural fistulas in daily clinical settings. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - November 27, 2016 Category: Respiratory Medicine Authors: Morikawa, S., Okamura, T., Minezawa, T., Goto, Y., Hayashi, M., Yamaguchi, T., Isogai, S., Mieno, Y., Yamamoto, N., Uozu, S., Nakanishi, T., Okazawa, M., Imaizumi, K. Tags: Original Research Source Type: research

Uncontrolled asthma and its risk factors in adult Chinese asthma patients
Conclusions: About half of the participants in this study had uncontrolled asthma. Treatment nonadherence is one of the significant predictors, which is very strongly associated with uncontrolled asthma. Efforts should be prioritized to promote patients’ treatment adherence to improve asthma control while attention is needed on rhinitis or obesity. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - November 27, 2016 Category: Respiratory Medicine Authors: Zhong, N., Lin, J., Zheng, J., Lai, K., Xie, C., Tang, K.-J., Huang, M., Chen, P., Wang, C. Tags: Original Research Source Type: research

High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
The high-strength formulation of extrafine beclometasone dipropionate/formoterol fumarate (BDP/Form) 200/6 µg has been developed to step up inhaled corticosteroid treatment, without increasing the dose of the bronchodilator, in patients who are not controlled with previous therapies. Two clinical studies have evaluated efficacy of high-strength BDP/Form as compared with another high-dose fixed combination and BDP monotherapy. Overall, data show that BDP/Form 200/6 μg improves lung function and has beneficial effects on symptoms, use of rescue medication and asthma control, with an acceptable safety profile compara...
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Corradi, M., Spinola, M., Petruzzelli, S., Kuna, P. Tags: Reviews Source Type: research

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
Angiogenesis is one of the hallmarks of cancer. Antivascular endothelial growth factor therapy, including bevacizumab, is therefore a major option in targeting angiogenesis, especially for the management of stage IV nonsquamous non-small cell lung cancer patients. This review focuses first on the data from clinical trials available to date regarding efficacy and safety of chemotherapy plus bevacizumab. This review then highlights the current remaining questions related to the use of this drug in daily practice and how the patients might be clinically and radiologically selected. Finally, this review explores the future dir...
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Greillier, L., Tomasini, P., Barlesi, F. Tags: Reviews Source Type: research

Notch signaling in lung diseases: focus on Notch1 and Notch3
Notch signaling is an evolutionarily conserved cell–cell communication mechanism that plays a key role in lung homeostasis, injury and repair. The loss of regulation of Notch signaling, especially Notch1 and Notch3, has recently been linked to the pathogenesis of important lung diseases, in particular, chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, pulmonary arterial hypertension (PAH), lung cancer and lung lesions in some congenital diseases. This review focuses on recent advances related to the mechanisms and the consequences of aberrant or absent Notch1/3 activity in the initiation and p...
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Zong, D., Ouyang, R., Li, J., Chen, Y., Chen, P. Tags: Reviews Source Type: research

End-of-life care in patients with advanced lung cancer
Despite advances in the detection, pathological diagnosis and therapeutics of lung cancer, many patients still develop advanced, incurable and progressively fatal disease. As physicians, the duties to cure sometimes, relieve often and comfort always should be a constant reminder to us of the needs that must be met when caring for a patient with lung cancer. Four key areas of end-of-life care in advanced lung cancer begin with first recognizing ‘when a patient is approaching the end of life’. The clinician should be able to recognize when the focus of care needs to shift from an aggressive life-sustaining approa...
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Lim, R. B. L. Tags: Reviews Source Type: research

Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence
Progress in the treatment of patients with advanced stage squamous cell non-small cell lung cancer (NSCLC) has been limited. An improvement in the understanding of tumor immunosurveillance has resulted in the development of the immune checkpoint inhibitors such as nivolumab. Nivolumab (Opdivo®), a human immunoglobulin (Ig)G4 anti-programmed death (PD)-1 monoclonal antibody, was the first PD-1 inhibitor approved in the treatment of patients with advanced stage squamous cell NSCLC following platinum-based chemotherapy. CHECKMATE 017, a randomized phase III study of second-line nivolumab versus docetaxel, significantly im...
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Lim, J. S. J., Soo, R. A. Tags: Reviews Source Type: research

Segmentectomy versus wedge resection for the treatment of high-risk operable patients with stage I non-small cell lung cancer: a meta-analysis
Conclusions: For patients with stage I NSCLC, segmentectomy results in higher survival rates than wedge resection, whereas the outcomes of wedge resection are comparable to those of segmentectomy for patients with stage Ia NSCLC with tumor size <= 2 cm. Considering the limitations and heterogeneity of the included studies, this conclusion should be further confirmed by rigorous randomized clinical trials. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Hou, B., Deng, X.-F., Zhou, D., Liu, Q.-X., Dai, J.-G. Tags: Original Research Source Type: research

Impact of the implementation of an evidence-based guideline on diagnostic testing, management, and clinical outcomes for infants with bronchiolitis
Conclusions: The development and implementation of a good quality bronchiolitis CPG is associated with a significant increase in the proportion of cases with an appropriate diagnosis and treatment of the disease in the context of a university-based hospital located in the capital of an LMIC. However, we could not demonstrate an improvement in clinically important outcomes such as any of the bronchiolitis severity parameters. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Henao-Villada, R., Sossa-Briceno, M. P., Rodriguez-Martinez, C. E. Tags: Original Research Source Type: research

Factors associated with experience of fatigue, and functional limitations due to fatigue in patients with stable COPD
Conclusions: Experiences of fatigue and functional limitation due to fatigue seem to be related mainly to psychological but also to physiological influencing factors, with depressive symptoms, insomnia problems and dyspnoea as the most prominent factors. Systemic inflammation was not associated with perception of fatigue but surfactant protein D was connected to some dimensions of the impact of fatigue (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Kentson, M., Tödt, K., Skargren, E., Jakobsson, P., Ernerudh, J., Unosson, M., Theander, K. Tags: Original Research Source Type: research

Spontaneous pneumomediastinum and subcutaneous emphysema as a complication of asthma in children: case report and literature review
Conclusions: Early identification of patients at risk of SPM would avoid the high number of under-diagnosed cases. Patients should be treated not only with supportive therapy but also with measures to achieve control of the underlying cause (such as poorly controlled asthma). (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Tortajada-Girbes, M., Moreno-Prat, M., Ainsa-Laguna, D., Mas, S. Tags: Original Research Source Type: research